Use of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosis

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Tukvadze, Nestani ^a   Kempker, Russell R ^b   Kalandadze, Iagor ^a   Kurbatova, Ekaterina ^b   Leonard, Michael K ^b   Apsindzelashvili, Rusudan ^a   Bablishvili, Nino ^a   Kipiani, Maia ^a   Blumberg, Henry M ^b  

^a National Center for Tuberculosis and Lung Diseases   (Georgia)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHIONAMIDE; ISONIAZID; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ARTICLE; BACTERIAL GENE; CODON; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG SENSITIVITY; GENE MUTATION; HUMAN; KATG GENE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PROTEIN BINDING; RPOB GENE; SENSITIVITY AND SPECIFICITY; SPUTUM CYTODIAGNOSIS; SPUTUM SMEAR; EVALUATION; GENETICS; METHODOLOGY; MICROBIOLOGY; MOLECULAR DIAGNOSIS; MUTATION; REPRODUCIBILITY; SPUTUM; UNITED STATES;

ANTITUBERCULAR AGENTS; GEORGIA; HUMANS; ISONIAZID; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; REPRODUCIBILITY OF RESULTS; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84856778048     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031563     Document Type: Article

References (26)

1. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375: 1830-1843.
2. WHO (2010) Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/20103 Geneva World Health Organization, 2010.
3. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, et al. (2009) Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 9: 153-161.
4. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, et al. (2000) Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA: the journal of the American Medical Association 283: 2537-2545.
5. WHO (2010) The Global Plan to Stop TB 2011-2015. WHO/HTM/STB/20102 Geneva, Switzerland WHO, 2010.
6. Genotype MTBDRplus, product page. http://www.hain-lifescience.de.en/products/microbiology/mycobacteria/genotype-mtbdrplus.html. Nehren, Germany. Hain Lifescience. [accessed August 15, 2011].
7. Ling DI, Zwerling AA, Pai M, (2008) GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology 32: 1165-1174.
8. World Health Organization, 2008 WHO Policy Statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis Geneva Available at http://www.who.int/tb/features_archive/policy_statement.pdf.
9. Dorman SE, (2010) New diagnostic tests for tuberculosis: bench, bedside, and beyond. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 50 (Suppl 3): S173-177.
10. WHO (2011) Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015:WHO progress report 2011. WHO/HTM/TB/20113 Geneva World Health Organization, 2010.
11. Parsons LM, Somoskovi A, Gutierrez C, Lee E, Paramasivan CN, et al. (2011) Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clinical microbiology reviews 24: 314-350.
12. WHO (2009) Guidelines for surveillance of drug resistance in tuberculosis-4th ed. WHO/HTM/TB/2009422 Geneva World Health Organization, 2009.
13. WHO (2008) Policy guidance on drug susceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008392 Geneva World Health Organization, 2008.
14. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, et al. (2009) Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42: 377-381.
15. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME, (2008) Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 177: 787-792.
16. Evans J, Stead MC, Nicol MP, Segal H, (2009) Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa. The Journal of antimicrobial chemotherapy 63: 11-16.
17. Hillemann D, Rusch-Gerdes S, Richter E, (2007) Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. Journal of clinical microbiology 45: 2635-2640.
18. Anek-Vorapong R, Sinthuwattanawibool C, Podewils LJ, McCarthy K, Ngamlert K, et al. (2010) Validation of the GenoType MTBDRplus assay for detection of MDR-TB in a public health laboratory in Thailand. BMC infectious diseases 10: 123.
19. Kent PT, Kubica GP, (1985) Public Health Mycobacteriology: a guide for the level III laboratory Atlanta, GA Centers for Disease Control.
20. Zhang Y, Yew WW, (2009) Mechanisms of drug resistance in Mycobacterium tuberculosis. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 13: 1320-1330.
21. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, et al. (2009) Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 48: 179-185.
22. Matthys F, Rigouts L, Sizaire V, Vezhnina N, Lecoq M, et al. (2009) Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. PLoS One 4: e7954.
23. Cox HS, Niemann S, Ismailov G, Doshetov D, Orozco JD, et al. (2007) Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 44: 1421-1427.
24. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, et al. (1994) inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230.
25. Hillemann D, Rusch-Gerdes S, Richter E, (2009) Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. Journal of clinical microbiology 47: 1767-1772.
26. Richards DC, Mikiashvili T, Parris JJ, Kourbatova EV, Wilson JC, et al. (2006) High prevalence of hepatitis C virus but not HIV co-infection among patients with tuberculosis in Georgia. The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 10: 396-401.